About 48 percent of women with advanced ovarian cancer saw sustained benefits from treatment with Nektar Therapeutics' experimental drug NKTR-102 in a mid-stage study, the company said.
Twenty-three percent of patients on a dose schedule of once every three weeks saw substantial shrinkage in their tumors, and 38 percent saw a marked reduction in the ovarian cancer biomarker CA-125.
The results from the study of 68 patients were presented at a meeting of the American Society of Clinical Oncology in Chicago.
"These results demonstrate that NKTR-102 holds great therapeutic potential for women battling ovarian cancer," said Dr. Ignace Vergote, head of obstetrics and gynecology and gynecologic oncology at the Catholic University of Leuven, Belgium, and the study's lead investigator.
About 230,000 women worldwide are diagnosed with ovarian cancer each year, and nearly 70 percent with advanced disease die within five years.
NKTR-102 is also being tested in two separate Phase 2 clinical trials in patients with metastatic breast cancer and colorectal cancer.
Nektar Drug Helps Ovarian Cancer Patients
Study: About 48 percent of women with advanced ovarian cancer saw sustained benefits from treatment with the experimental drug.
We've upgraded our reader commenting system. Learn more about the new features.